(DRRX) Durect - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2666051048
DRRX: Medicines, Osmotic Pumps, Pain Products, Hepatitis Treatments
DURECT Corporation (NASDAQ:DRRX) is a biopharmaceutical company focused on developing innovative medicines, with a strong emphasis on its epigenetic regulator program. The companys lead product, larsucosterol (DUR-928), is an endogenous, orally bioavailable small molecule currently in Phase IIb clinical trials. DUR-928 is being investigated for its regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival, primarily targeting alcohol-associated hepatitis. Additionally, it has completed Phase Ib clinical trials for nonalcoholic steatohepatitis, showcasing its potential in addressing liver-related conditions.
Beyond DUR-928, DURECT offers the ALZET product line, which includes osmotic pumps and accessories designed for research in laboratory animals. These pumps are essential tools in preclinical studies, enabling precise drug delivery in mice, rats, and other animals. The company also markets POSIMIR, a post-surgical pain product that delivers bupivacaine over three days in adults, and Methydur, intended for treating attention deficit hyperactivity disorder. DURECTs distribution strategy involves a direct sales force in the U.S. and a network of international distributors, ensuring broad market reach.
DURECT has established strategic collaborations with Virginia Commonwealth University Intellectual Property Foundation, Indivior UK Ltd., and Innocoll Pharmaceuticals Limited, enhancing its research and development capabilities. Incorporated in 1998 and headquartered in Cupertino, California, the company maintains a strong web presence at https://www.durect.com.
Based on the provided data, the 3-month forecast for DURECT Corporation (NASDAQ:DRRX) suggests continued sideways movement with potential decline. The stock price is currently at $0.77, with a 20-day average volume of 35,185. The SMA20 at $0.78 and SMA50 at $0.81 indicate a possible downtrend. The low ATR of $0.06 points to minimal volatility. Fundamentally, with a market cap of $24.49M and P/S ratio of 2.85, the stock may face valuation pressures, while the high P/B ratio of 20.15 could signal overvaluation. These factors collectively suggest a cautious outlook for the next quarter.
Additional Sources for DRRX Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
DRRX Stock Overview
Market Cap in USD | 24m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2000-09-28 |
DRRX Stock Ratings
Growth 5y | -86.0% |
Fundamental | -22.0% |
Dividend | 0.0% |
Rel. Strength Industry | -37.8 |
Analysts | 4.33/5 |
Fair Price Momentum | 0.54 USD |
Fair Price DCF | - |
DRRX Dividends
No Dividends PaidDRRX Growth Ratios
Growth Correlation 3m | -44.6% |
Growth Correlation 12m | -47.2% |
Growth Correlation 5y | -94.1% |
CAGR 5y | -39.99% |
CAGR/Max DD 5y | -0.41 |
Sharpe Ratio 12m | -0.51 |
Alpha | -36.65 |
Beta | -0.74 |
Volatility | 69.65% |
Current Volume | 80.9k |
Average Volume 20d | 32.8k |
As of March 15, 2025, the stock is trading at USD 0.86 with a total of 80,871 shares traded.
Over the past week, the price has changed by +12.36%, over one month by +11.83%, over three months by -8.22% and over the past year by -37.23%.
Neither. Based on ValueRay Fundamental Analyses, Durect is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -21.99 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DRRX as of March 2025 is 0.54. This means that DRRX is currently overvalued and has a potential downside of -37.21%.
Durect has received a consensus analysts rating of 4.33. Therefor, it is recommend to buy DRRX.
- Strong Buy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, DRRX Durect will be worth about 0.6 in March 2026. The stock is currently trading at 0.86. This means that the stock has a potential downside of -32.56%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 6.8 | 684.9% |
Analysts Target Price | 6.8 | 684.9% |
ValueRay Target Price | 0.6 | -32.6% |